2011
Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative group study (SWOG S0356).
Bohanes P, Goldman B, Leichman L, Blanke C, Iqbal S, Thomas C, Corless C, Billingsley K, Danenberg K, Zhang W, Benedetti J, Gold P, Lenz H. Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative group study (SWOG S0356). Journal Of Clinical Oncology 2011, 29: 4023-4023. DOI: 10.1200/jco.2011.29.15_suppl.4023.Peer-Reviewed Original Research
2008
Response: Re: Residual Treatment Disparities After Oncology Referral for Rectal Cancer
Morris A, Billingsley K, Hayanga A, Matthews B, Baldwin L, Birkmeyer J. Response: Re: Residual Treatment Disparities After Oncology Referral for Rectal Cancer. Journal Of The National Cancer Institute 2008, 100: 1740-1740. PMID: 18477800, PMCID: PMC2766763, DOI: 10.1093/jnci/djn396.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlack or African AmericanChemotherapy, AdjuvantConfidence IntervalsDecision MakingFemaleHealth Services AccessibilityHealthcare DisparitiesHumansLogistic ModelsMaleMedical OncologyMedical Record LinkageMedicareNeoplasm StagingPractice Patterns, Physicians'Radiation OncologyRadiotherapy, AdjuvantRectal NeoplasmsReferral and ConsultationSEER ProgramUnited StatesWhite PeopleConceptsRectal cancerAdjuvant therapyBlack patientsWhite patientsRadiation oncologistsAdjuvant treatmentMedical oncologistsEnd Results-Medicare dataProvider decision makingPatient-provider interactionsFrequency of consultationsLow treatment ratesClinical characteristicsElderly patientsConsultation ratesOncology referralTreatment disparitiesPatient preferencesProvider characteristicsRadiation therapyPatientsOncologistsTherapyStage IITreatment ratesSurvival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population
Dobie S, Warren J, Matthews B, Schwartz D, Baldwin L, Billingsley K. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer 2008, 112: 789-799. PMID: 18189291, PMCID: PMC3103394, DOI: 10.1002/cncr.23244.Peer-Reviewed Original ResearchConceptsStage II patientsRectal cancer patientsStage III patientsII patientsCancer patientsStage IIAdjuvant radiationAdjuvant therapyIII patientsGeneral populationStage II rectal cancer patientsLower cancer-related mortalityReceipt of chemoradiationCancer mortality riskCancer-related mortalityMultivariate logistic regressionAdjusted riskAdjuvant chemoradiationChemotherapy receiptSurgical resectionSurvival benefitSEER-MedicareTherapy adherencePatient groupRadiation therapy